Disease Areas Mar 30, 2023 Gastric Cancer Risk Variants, Pathogen Interactions Found in Retrospective Study Mar 30, 2023 PDS Biotech to Begin Phase III Trial of Immunotherapy in HPV 16-Positive Head and Neck Cancer Mar 29, 2023 EGFR-Mutant NSCLC Patients See Similar Survival in Upfront Tagrisso Versus Sequential Treatment Premium Mar 29, 2023 NCCN Adds Mirati Therapeutics' Krazati to Guidelines for KRAS-Mutant NSCLC With Brain Metastases Mar 29, 2023 European Commission Approves Libtayo in PD-L1-Positive Non-Small Cell Lung Cancer Mar 29, 2023 NICE Backs Merck's Keytruda for PD-L1-Expressing Cervical Cancer Mar 28, 2023 Breast Cancer Study Leads to New Susceptibility Gene, Potential Treatment Strategies Mar 28, 2023 Incyte's Pemazyre Approved in Japan for FGFR1-Positive Rare Blood Cancers Mar 28, 2023 Cardiff Oncology Begins Phase II Onvansertib Trial in KRAS-, NRAS-Mutant Colorectal Cancer Mar 27, 2023 Novartis Seeks Adjuvant Kisqali Approval After Phase III Readout in Early-Stage Breast Cancer Mar 27, 2023 Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer Mar 27, 2023 Transcriptomic Classification of Pediatric Cancers Shows Potential to Improve Clinical Diagnoses Premium Mar 24, 2023 Black Women With High Cancer Risk Lack Access to Genetics Experts, Specialists, OSU Study Finds Premium Mar 24, 2023 Astellas Bullish on Zolbetuximab's Prospects in Gastric Cancer After Two Positive Phase III Readouts Premium Mar 24, 2023 William Blair Initiates Coverage of MDxHealth With Outperform Rating Mar 23, 2023 Artera Raises $90M to Market Test for Assessing Prostate Cancer Progression, Treatment Benefit Premium Mar 23, 2023 Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer Mar 23, 2023 BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors Mar 23, 2023 Onconova Therapeutics, Pangea Biomed Collaborate on AI-Driven Cancer Biomarker Study Mar 23, 2023 Baylor Team Aims to Identify Chemo Toxicity Biomarkers in Latino Pediatric Leukemia Patients Premium Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
